| Richard M. Chasen, M.D., F.A.C.G. |
|
| Education: |
University of Rochester NY; B.A. 1971
|
Howard University College of Medicine
Washington, D.C.: 1973-1977: M.D. 1977 |
| Post-Graduate Training: |
| Gastroenterology Fellowship; Johns Hopkins University School
of Medicine: Baltimore, Maryland 1980-1982 |
| Proficiency in Endoscopic procedures, polypectomy, liver biopsy,
laser endoscopy |
| Residency, Greater Baltimore Medical Center 1977-1980 |
| Chief Resident, Internal Medicine; Greater Baltimore Medical
Center, Baltimore, Maryland 1979-1980 |
| Hospital Privileges: |
Washington Adventist Hospital
Laurel Regional Hospital
Howard County General Hospital |
| Hospital Positions: |
| Chief-Subdivision of Gastroenterology; Laurel Regional Hospital,
Laurel, Maryland 1985-1990 |
| Chairman Department of Internal Medicine, Laurel Regional Hospital,
1993- 1995 |
| Chairman-Medical Review Committee of Department of internal Medicine
at Washington Adventist Hospital 1992-1995 |
| Vice-Chairman Department of internal Medicine at Washington Adventist
Hospital 1998- 2000 |
Maryland Digestive Disease Center
7350 Van Dusen Rd. Suite 210
Laurel, MD 20707 |
Ambulatory Endoscopy Center of Maryland
7350 Van Dusen Road Suite 230
Laurel, MD 20707
July. 1993-present |
Maryland Digestive Disease Research LLC
7350 Van Dusen Road Suite 360
Laurel, MD 20707
Principal Investigator, Co-owner 1997-present |
| Board Certification |
| Internal Medicine: Gastroenterology |
Private Practice of Gastroenterology since
Former Medical Director, Laurel Regional Hospital,
Renaissance Program (Alcohol and Drug Rehabilitation Program)
|
| Medical Society Membership: |
American Gastroenterological Association
Fellow- American College of Gastroenterology
American Cancer Society
Medical Chirurgical Faculty of Maryland
William Clark Society
Maryland Society of Gastrointestinal Endoscopy
Montgomery County Medical Society
American College of Gastrointestinal Endoscopy
Crohn’s and Colitis Foundation |
| Research Trials: |
| A phase III, International, Multicenter, Double-Blind, Placebo
Controlled Study of the Safety, Efficacy, and Tolerability of Intravenous
XXX in Subjects with Moderately to Severely Active Crohn’s
Disease |
| A single-Center, Randomized, Single-Blind, Parallel Group Evaluation
to the effectiveness, and safety following Administration of a
suspensions Made from XXX coated Powder for Bowel Preparation Prior
to Elective Colonoscopy. |
| A Comparative Efficacy and Safety Study of XXX Delayed-Release
Capsules (40 mg qd) Versus Placebo for the Prevention of Gastric
Ulcers Association with Daily NSAID Use in Patients at Risk |
| A Randomized, Placebo-controlled, Double-blind Trial to Evaluate
the Safety and Efficacy of XXX in Patients with Active Ulcerative
Colitis |
| A Randomized, Placebo-Controlled Trail of XXX for Treatment of
Ulcerative Colitis |
| A Multicenter Comparison of the XXX Panel with XXX for the Detection
of Colorectal Neoplasia in Average-Risk Patients (The Colorectal
Cancer Screening Study) |
| A Double-Bind, Randomized, 6 week, Parallel-Group Design Clinical
Trial in Patients with Madly to Moderately Active Ulcerative Colitis
to Assess the Safety and Efficacy of XXX 4.8 g/day (800 mg tablet)
Versus XXX 2.4 g/day (400 mg tablet) |
| Dose Comparison Study of XXX + XXX for patients with Chronic
Hepatitis C Who Have Not Responded to Standard XXX + XXX |
| A Double- Blind, Placebo-Controlled, Randomized Multicenter Study
to Investigate the Safety and Efficacy of 2 mg XXX of XXX over
12 Weeks Followed by a 4-week Rerandomized Treatment Period in
Diarrhea-Predominant Irritable Bowel Syndrome Subjects |
| A Prospective, Randomized, Multi-Center, Open- Label, Comparative
Safety Study of XXX plus XXX Treatment vs. a Twelve-Week Treatment
Delay in Patients with Chronic Hepatitis C |
| A randomized Double Blind Trial Comparing the Early Profile of
Heartburn Relief Associated with XXX, 20 mg once daily Vs. XXX,
20 mg once daily in Gastroesophagael Reflux Disease Patients with
an Acute or Documented History of Erosive Esophagitis |
| A Multicenter, Double-Blind, Placebo Controlled Crossover Study
to Assess the Acute Prokinetic Efficacy and Safety of XXX Controlled
Release (CR), 150 mg and XXX CR, 300 mg in Subjects with Gastroesophagael
Reflux Disease |
| A study of the Efficacy and Safety of XXX-XXX Tabs compared with
NuLYTELY as a Purgative Agent for patients Undergoing Colonoscopic
Evaluation |
| A Multicenter, Randomized, Double- Blind, Safety and Efficacy
Study of XXX 40 mg qd with Clarithromycin 500 mg bid Compared to
XXX 40 mg qd with Amoxicillin 1 gm bid plus Clarithromycin 500
mg bid for the Eradication of Helicobacter Pulora in Subjects with
Active Duodenal Ulcer or History of Duodenal Ulcer Disease |
| A 26- week, International, Multicenter, Randomized, Double- Blind,
Double-Dummy Parallel Group Active Controlled Endoscopic Study
of Gastro duodenal Effects of XXX (400 mg and 800 mg) in patients
with rheumatoid arthritis using XXX (800 mg tid) and XXX (200 mg
bid) as comparators |
| Publications: |
| “Lack of Difference in Response to Rebetron by Race in
prior Interferon Nonresponders with Chronic Hepatitis C.” Abstract.
American College of Gastroenterology. October 2000. |
| “Efficacy and Safety of Sodium Phosphate Tablets Compared
with PEG solution in Colon Cleansing: Two Identically Designed,
Randomized, Controlled, Parallel Group, Multicenter Phase III Trials.” |
